source
- Nonprofits launch ultra-rare immune disease gene therapy Waskyra at $3.25 million priceTwo nonprofit organizations have received FDA approval for a gene therapy that targets an ultra-rare immune disorder. The therapy, called Waskyra, is now being launched with a list price of $3.25…
- Merck and Daiichi Sankyo pull accelerated approval request for lung cancer ADCMerck and Daiichi Sankyo have voluntarily withdrawn their application for accelerated approval of the antibody-drug conjugate ifinatamab deruxtecan. The FDA indicated that the data package did not…